Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Company Profile and bullboard matches:

EMCR
Sort by: Date|Relevance

US Inflation Reduction Act Could Supercharge Canada’s Cobalt-Related Sectors

Written by: Jessica N. Abraham The rapidly emerging battery metals market just gained a major driver that will last for decades.That driver is the US Inflation Reduction Act (IRA), which was...

Ovid Therapeutics Posts Positive Data from Phase 2 Seizure Reduction Trial

Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies. Shares of Ovid Therapeutics Inc. (OVID:NASDAQ) are tra...

Alamos Gold Shares Rise on Royalty Repurchase and Mining Cost Reduction

Shares of Alamos Gold traded 15% higher after the firm reported that it has repurchased a 3% net smelter return royalty on its Island Gold mine located in northern Ontario. Intermediate gold producer Alamos Gold Inc. (AGI:TSX; AGI:NYSE) today announced t...

dynaCERT on Haywood Securities’ radar, ESG benefactor ready to scale

dynaCERT Inc. (TSX-V: DYA) (OTCQB: DYFSF) (Frankfurt: DMJ) is the subject of coverage by analysts at Haywood Securities which issued an ‘Uncovered Radar Flash – Watchlist Report’ on June 2, 2020 entitled “ An ESG Benefactor; A Carbon Emission Reduction Techno...

dynaCERT Now Leader in Carbon Credit Market, Multi-Trillion Dollar Global Opportunity

dynaCERT’s HG technology is already proven (on diesel trucks) to result in up to 88.7% reduction in NOx emissions, ~50% reduction in CO, ~10% reduction in CO2, up to 57.1% reduction in Total Hydrocarbon emissions, 50%+ reduction in particulate matter (no...

dynaCERT Invited to Speak at World Climate Summit on Future of World Carbon Credits, ...

dynaCERT Invited to Speak at World Climate Summit on Future of World Carbon Credits, Sales Growing Exponentially dynaCERT Inc. (TSX-V: DYA) (OTCQB: DYFSF) (Frankfurt: DMJ) CEO & President, Jim Payne, was interviewed on Bloomberg BNN (Business News Network) this week in...

dynaCERT first institutional coverage; >250% near-term upside, no competition in $6 Trillion market

dynaCERT’s Fuel-Saving and Carbon Emission Reduction Technology is award winning and on an accelerated growth adoption curve that is expected to translate into significant sales and upside share price revaluation. dynaCERT's proprietary HG technology has ...

dynaCERT attracting major strategic investors entering 2020, exponential growth potential

Order of Canada member Eric Sprott, plus Dr. Jorg Mosolf (of Europe’s MOSOLF Group) are two of the most recent strategic investors that have taken significant shareholder positions and made business commitments in DYA.V. dynaCERT is at the forefront of t...

BlackRock CEO says climate crisis will reshape finance, DynaCERT approaches escape velocity

631 investors from around the world, representing ~US$37 trillion in assets, signed a letter in December urging governments to step up their efforts against climate change. This letter put pressure on major asset managers to articulate strategies around sustainability. ...

Arbutus Biopharma Trades 25% Higher on Phase 1 Hepatitis B Results

Shares of Arbutus Biopharma traded higher after the company reported significant and continuous reduction in HBsAg in 12 chronic hepatitis B subjects using 60 mg dosage of its AB-729 drug. Clinical-stage biopharmaceutical company Arbutus Biopharma Corp. (ABUS:NASD...
1 2 3 4 5 6 7 8 9 10 ...